DOI QR코드

DOI QR Code

Clinical Features and Survival Analysis of Very Young (Age<35) Breast Cancer Patients

  • Wei, Xue-Qing (Department of Ultrasonic Diagnosis and Treatment, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy) ;
  • Li, Xing (Department of Ultrasonic Diagnosis and Treatment, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy) ;
  • Xin, Xiao-Jie (Department of Ultrasonic Diagnosis and Treatment, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy) ;
  • Tong, Zhong-Sheng (Department of Breast Cancer Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy) ;
  • Zhang, Sheng (Department of Ultrasonic Diagnosis and Treatment, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy)
  • Published : 2013.10.30

Abstract

Objectives: To compare the clinicalpathological features and prognosis between premenopausal breast cancer patients aged of <35 and ${\geq}35$ years old. Methods: The clinical data and survival status of 1498 cases premenopausal operable breast cancer treated in our hospital from 2002.1 to 2004. 12 were collected, 118 cases were aged <35. They were divided into 4 groups: Luminal A, Luminal B, HER2-positive, Triple-negative. The disease free survival (DFS) and overall survival (OS) were identified. Results: The 5-year DFS and OS rates were significantly lower in age<35 than in $age{\geq}35$ patients. In the Luminal B, HER2-positive, Triple-negative group, the 5-year recurrence risk was higher in age<35 than in $age{\geq}35$ patients, and age<35 patients' 5-year death risk was higher only in Luminal B, Triple-negative group. Regardless of whether lymph node involved, age<35 patients had a bad prognosis in both DFS and OS. Conclusions: Compared with premenopausal age ${\geq}35$ breast cancer, age<35 patients had a worse outcome.

Keywords

References

  1. Ahn SH, Son BH, Kim SW, et al (2007). Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol, 25, 2360-8. https://doi.org/10.1200/JCO.2006.10.3754
  2. Bauer KR, Brown M, Cress RD, et al (2007). Descriptive analysis of estrogen receptor(ER)-negative, progesterone receptor(PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer, 109, 1721-8. https://doi.org/10.1002/cncr.22618
  3. Cancello G, Maisonneuve P, Rotmensz N, et al (2010). Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol, 21, 1974-81. https://doi.org/10.1093/annonc/mdq072
  4. Chung M, Chang HR, Bland KI, et al (1996).Younger women with breast carcinoma have a poorer prognosis than older women. Cancer, 77, 97-103. https://doi.org/10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3
  5. Colleoni M, Rotmensz N, Robertson C, et al (2002) . Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol, 13, 273-9.
  6. FitzGerald MG, MacDonald DJ, Krainer M, et al (1996). Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med, 334, 143-9. https://doi.org/10.1056/NEJM199601183340302
  7. Gajdos C, Tartter PI, Bleiweiss IJ, et al (2000). Stage 0 to stage _ breast cancer in young women. J Am Coll Surg, 190, 523-9. https://doi.org/10.1016/S1072-7515(00)00257-X
  8. Goldhirsch A, Glick JH, Gelber RD, et al (1998). Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst, 90, 1601-8. https://doi.org/10.1093/jnci/90.21.1601
  9. Goldhirsch A, Glick JH, Gelber RD, et al (2001). Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol, 19, 3817-27.
  10. Han W, Kim SW, Park IA, et al (2004).Young age: An independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer, 17, 82.
  11. Kim JK, Kwak BS, Lee JS, et al (2007). Do very young Korean breast cancer patients have worse outcomes? Ann Surg Oncol, 14, 3385-91. https://doi.org/10.1245/s10434-006-9345-9
  12. Kim JK, Kwak BS, Lee JS, et al (2007). Do very young Korean breast cancer patients have worse outcomes? Ann Surg Oncol, 14, 3385-91. https://doi.org/10.1245/s10434-006-9345-9
  13. Kothari AS, Beechey-Newman N, D Arrigo C, et al (2002). Breast carcinoma in women age 25 years or less. Cancer, 94, 606-14. https://doi.org/10.1002/cncr.10273
  14. Madaras L, Baranyak Z, Kulka J, et al (2013). Retrospective analysis of clinicopathological characteristics and family history data of early-onset breast cancer: a single-institutional study of hungarian patients. Pathol Oncol Res, 19, 723-9. https://doi.org/10.1007/s12253-013-9635-z
  15. Meng J, Lang RG, Fan Y, Fu L (2007). [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis]. Zhonghua Zhong Liu Za Zhi, 29, 284-8. [Article in Chinese]
  16. Muscolino G, Villani C, Bedini AV, et al (1987). Young age is not an ominous prognostic factor in breast cancer patients. Tumori, 73, 233-5.
  17. Osborne CK, Shou J, Massarweh S, et al (2005). Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res, 11, 865-70.
  18. Robson M, Gilewski T, Haas B, et al (1998). BRCA-associated breast cancer in young women. J Clin Oncol, 16, 1642-9.
  19. Schmidt RT, Tsangaris TN, Cheek JH (1991). Breast cancer in women under 35 years of age. Am J Surg, 162, 197-201. https://doi.org/10.1016/0002-9610(91)90068-O
  20. Vrieling C, Collette L, Fourquet A, et al (2003). Can patient-treatment-and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer, 39, 932-44. https://doi.org/10.1016/S0959-8049(03)00123-0
  21. Winchester DP(1996).Breast cancer in young women. Surg Clin North Am, 76, 279-87. https://doi.org/10.1016/S0039-6109(05)70439-4

Cited by

  1. Clinicopathologic Features and Molecular Subtypes of Breast Cancer in Young Women (Age ≤35) vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6665
  2. Distinct Postsurgical Management in Young and Elderly Breast Cancer Patients Results in Equal Survival Rates vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7843
  3. Prognosis of Breast Cancer Patients Underwent Surgery in a Developing Country vol.06, pp.09, 2015, https://doi.org/10.4236/jct.2015.69088
  4. Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1207-z
  5. Breast Cancer at Extreme Ages - a Comparative Analysis in Chile vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1455
  6. Young Women with Breast Cancer in the United States and South Korea: Comparison of Demographics, Pathology and Management vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2531
  7. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database vol.11, pp.10, 2016, https://doi.org/10.1371/journal.pone.0165409
  8. Clinicopathological features and survival of early stage breast cancer in northwest China: A population-based retrospective study of 1287 patients pp.17597706, 2017, https://doi.org/10.1111/1759-7714.12503
  9. TNM stage at diagnosis is more predictive of prognosis than pathological complete response in young breast cancer treated with neoadjuvant chemotherapy pp.0959-4973, 2017, https://doi.org/10.1097/CAD.0000000000000577